{
    "clinical_study": {
        "@rank": "9964", 
        "arm_group": [
            {
                "arm_group_label": "Compound tripterygium gel", 
                "arm_group_type": "Experimental", 
                "description": "Patients were treated with Compound tripterygium gel."
            }, 
            {
                "arm_group_label": "Placebo gel", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The placebo gel was used to be a comparator of Compound tripterygium gel."
            }
        ], 
        "brief_summary": {
            "textblock": "Rheumatoid Arthritis (RA) is an autoimmune disease that results in a chronic inflammatory\n      disorder that may affect many synovial joints, and may cause serious disability. It has been\n      confirmed that tripterygium extract has effects of anti-inflammatory, immunosuppressive and\n      cartilage protection. This is a prospective randomized controlled study to evaluated the\n      efficacy and safety of external application with compound tripterygium gel in treating of\n      patients with rheumatoid arthritis (RA)."
        }, 
        "brief_title": "External Therapy With Compound Tripterygium Gel for Decreasing Disease Activity in Patients With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented diagnosis of rheumatoid arthritis, as defined by the American Rheumatism\n             Association 1987 Revised Criteria or European League Against Rheumatism criteria\n             (2009).\n\n          -  Patients must have moderately to severely active RA,and the DAS-28 score should be\n             from 3.2 to 5.1.\n\n          -  If taking disease modifying antirheumatic drug (DMARDs)(e.g.Methotrexate), subject\n             must have been on a stable dose for \u2265 3 months prior to randomization.\n\n          -  If taking non-steroidal anti-inflammatory drugs (NSAIDs), subject must have been on a\n             stable dose for \u2265 4 weeks prior to randomization.\n\n          -  16 to 65 years old, having signed the informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients who have skin burst or allergies.\n\n          -  Patients with sever diseases in Cardiovascular, brain, lung, liver, kidney and\n             hematopoietic system.\n\n          -  Patients who have been treated by tripterygium, hormones or biological agents.\n\n          -  Patients who have not been treated by DMARDs before.\n\n          -  Patients who are unwilling to comply with all study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "184", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01961505", 
            "org_study_id": "Z111107058811104"
        }, 
        "intervention": [
            {
                "arm_group_label": "Compound tripterygium gel", 
                "description": "The Compound tripterygium gel were smeared evenly in the selected joint surface for one hour once a day for 8 weeks.\uff08Dosage\uff1awrist joints 3ml, knee joints 10 ml, ankle usage 5 ml\uff09", 
                "intervention_name": "Compound tripterygium gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo gel", 
                "description": "The Placebo gel were smeared evenly in the selected joint surface for one hour once a day for 8 weeks.\uff08Dosage\uff1awrist joints 3ml, knee joints 10 ml, ankle usage 5 ml\uff09", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 9, 2013", 
        "number_of_arms": "2", 
        "official_title": "A 8-Week, Double Blind, Randomized Study to Determine the Effects of External Therapy With Compound Tripterygium Gel, in Subjects With Active Rheumatoid Arthritis.", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "China: Beijing Municipal Science and Technology Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP) change from baseline of Compound tripterygium versus placebo", 
            "safety_issue": "No", 
            "time_frame": "Baseline and at 4\uff0c8  weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01961505"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guang'anmen Hospital of China Academy of Chinese Medical Sciences", 
            "investigator_full_name": "Quan Jiang", 
            "investigator_title": "director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Guang'anmen Hospital of China Academy of Chinese Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guang'anmen Hospital of China Academy of Chinese Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}